Phase 3 Trial Supports Amivantamab Plus Lazertinib Over ...
Amivantamab plus lazertinib showed superior progression-free survival over osimertinib alone in advanced EGFR+ NSCLC, with a 30% reduced risk of disease progression or death. The combination also reduced extracranial progression risk by 32%. Safety profiles were manageable, with higher rates of EGFR- and MET-related adverse events.
Related Clinical Trials
Reference News
Phase 3 Trial Supports Amivantamab Plus Lazertinib Over ...
Amivantamab plus lazertinib showed superior progression-free survival over osimertinib alone in advanced EGFR+ NSCLC, with a 30% reduced risk of disease progression or death. The combination also reduced extracranial progression risk by 32%. Safety profiles were manageable, with higher rates of EGFR- and MET-related adverse events.